388 results
Page 5 of 20
8-K
EX-99.1
2t0lgu9rl2uehqw3o2rm
1 Nov 19
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
6:54am
8-K
EX-99.3
1ffd em2vte736
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K
EX-99.2
fk0opa3adw
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K
EX-99.1
l8engnz5uaos
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K/A
EX-99.1
pl4zw1x fan048af
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
10:33am
8-K
EX-99.1
cg08px3j vt
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
6:38am
8-K
EX-99.1
uq0 rn625qn
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
8-K
6yxqyd6eqk
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
8-K
r8m1y632z8
15 May 19
Other Events
6:39am
8-K
EX-99.1
5omxmxx1
3 May 19
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
6:36am
8-K
pzdt 9tnxjnm
1 Mar 19
Entry into a Material Definitive Agreement
7:02am
8-K
EX-99.1
phb1h1cdwl4i
8 Feb 19
ImmunoGen Reports Recent Progress and 2018 Operating Results
6:37am
8-K/A
w0ly kdae8enr4hzhgm
8 Jan 19
Results of Operations and Financial Condition
4:59pm
8-K
5k4ie2awgy4nx rn
8 Jan 19
Results of Operations and Financial Condition
4:07pm